Complications and mortality of venovenous extracorporeal membrane oxygenation in the treatment of neonatal respiratory failure: a systematic review and meta-analysis

CURRENT STATUS: UNDER REVIEW

BMC Pulmonary Medicine  BMC Series

Jing Xiong
Chongqing Medical University Affiliated Children's Hospital

Li Zhang
Chongqing Medical University Affiliated Children's Hospital

Lei Bao
Chongqing Medical University Affiliated Children's Hospital

Corresponding Author
400702@hospital.cqmu.edu.cn
ORCiD: https://orcid.org/0000-0001-5675-9014

DOI: 10.21203/rs.2.11328/v3

SUBJECT AREAS
  Pulmonology  Pediatrics

KEYWORDS
  extracorporeal membrane oxygenation, respiratory failure, systematic reviews, meta-analysis, neonate
Abstract
Background: Extracorporeal membrane oxygenation (ECMO) has been increasingly used for severe neonatal respiratory failure refractory to conventional treatments. To systematically evaluate the complications and mortality of venovenous ECMO (VV ECMO) in the treatment of neonatal respiratory failure, we performed a systematic review and meta-analysis of all the related studies.

Methods: PubMed, Embase, and Cochrane Library were searched. The retrieval period was from the establishment of the database to February 2019. Two investigators independently screened articles according to the inclusion and exclusion criteria. The quality of article was assessed by the Newcastle-Ottawa scale (NOS). The meta-analysis was performed by Stata 15.0 software.

Results: Four observational studies were included, with a total of 347 newborns. VV ECMO was used for neonates with refractory respiratory failure unresponsive to maximal medical therapy. Median ages of the newborns at cannulation were 43.2 hours, 23 hours, 19 hours, and 71 hours in the included four studies, respectively. The overall mortality at hospital charge was 12% (5%-18%) with a heterogeneity of I² =73.8% (p=0.01). Two studies reported mortality during ECMO and after decannulation, with 10% (0.8%-19.2%) and 6.1% (2.6%-9.6%), respectively. The most common complications associated with VV ECMO were: pneumothorax (20.6%), hypertension (20.4%), cannula dysfunction (20.2%), seizure (14.9%), renal failure requiring hemofiltration (14.7%), infectious complications (10.3%), thrombi (7.4%), intracranial hemorrhage or infarction (6.6%), hemolysis (5.3%), cannula site bleeding (4.4%), gastrointestinal bleeding (3.7%), oxygenator failure (2.8%), other bleeding events (2.8%), brain death (1.9%), and myocardial stun (0.9%).

Conclusion: The overall mortality at discharge of VV ECMO in the treatment of neonatal respiratory failure was 12%. Although complications are frequent, the survival rate during hospitalization is still high. Further larger samples, and higher quality of randomized controlled trials (RCTs) are needed to clarify the efficacy and safety of this technique in the treatment of neonatal respiratory failure.

Background
Severe neonatal respiratory failure is associated with substantial mortality [1-2]. Despite the great development of mechanical management and some other conventional therapies, mortality is still
high, and prognosis of neonates with extremely low oxygenation is especially poor [3]. Some complications such as ventilator-induced lung injury caused by mechanical ventilation may also affect the prognosis in return [4]. Extracorporeal membrane oxygenation (ECMO) is a rescue therapy for the treatment of severe neonatal respiratory failure refractory to high-frequency oscillatory ventilation (HFOV), pulmonary surfactant (PS) replacement, inhaled nitric oxide (iNO), and other conventional treatments [5-7]. Nowadays, ECMO is used to treat various reversible neonatal diseases, the most common diagnoses are meconium aspiration syndrome (MAS), persistent pulmonary hypertension of newborn (PPHN), and congenital diaphragmatic hernia (CDH) [6]. With the development of new therapies such as HFOV, exogenous surfactant therapy, and iNO, fewer patients with MAS, PPHN and RDS are supported by ECMO [8-10]. However, the survival rate of neonates with MAS has been sustained highest, approximately 94%. The survival rates of neonates with RDS and PPHN come to the next, with 84% and 77%, respectively. Whereas patients with CDH had the worst survival in this cohort of patients, approximately 51% [6]. There are two types of ECMO that are mostly used, one is venoarterial ECMO (VA ECMO) that provide both respiratory and cardiac support; the other is venovenous ECMO (VV ECMO) that provide solely respiratory support. In this study, we aimed to evaluate the incidence of complications and in-hospital mortality of VV ECMO in the treatment of neonatal respiratory failure.

Methods

Literature search

We conducted a systematic review and meta-analysis in accordance with Meta-analysis of Observational Studies in Epidemiology (MOOSE) and the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines [13-14]. Pubmed, Embase, and Cochrane library were searched systematically for articles reporting on VV ECMO in the treatment of neonatal respiratory failure. The retrieval period was from the establishment of the database to February 2019. We used Mesh terms with the following search strategies: (“extracorporeal membrane oxygenation” OR “Oxygenators, membrane”) AND (“Adult respiratory distress syndrome” OR “Respiratory insufficiency”) AND “infant, newborn”. Language was restricted to English only. We also searched
references of included articles to identify additional studies. Two investigators reviewed the citations independently.

**Selection criteria**

The title and abstract of citations were screened initially and full text was reviewed with the following inclusion criteria: (a) Randomized controlled trials (RCTs) and quasi-randomized controlled trials or observational studies; (b) Neonates with respiratory failure; (c) Neonates receiving VV ECMO, if VV ECMO and VA ECMO mixed, only studies reporting on independent outcomes for each mode were included, or the percentage of VA ECMO usage rate in the study was less than 10%, which produced negligible effect on the statistical analysis. (d) Studies reporting on complications and mortality during hospitalization. (e) Neonates more than 50. Articles that met all the inclusion criteria were included. A sample size cut-off of 50 VV ECMO cases and the percentage cut-off of 10% VA ECMO cases per study were established to limit the undue influence of anecdotal cases and to minimize publication bias, in keeping with prior systematic review and meta-analysis in adults [15]. Exclusion criteria including: (a) Case report, review, conference abstract, animal experiment, systematic review, meta-analysis and so on; (b) Duplicated studies; (c) Studies registered in the extracorporeal life support organization (ELSO) database; (d) Less than 50 patients; (e) Studies without available outcomes of interest. The corresponding authors were contacted to request additional data.

**Data extraction and quality assessment**

Two investigators (JX and LZ) performed data extraction independently, disagreements were settled by a third investigator (LB). The inclusion and exclusion criteria were strictly followed in the process of literature screening. The following data were collected: demographic data of patients, features of included studies, procedural details and equipment information of ECMO including maximum cannula size, pump type, oxygenator type, and cannula type. The main outcomes of interest included mortality during ECMO or at discharge and incidence of complications. We used the Newcastle-Ottawa scale (NOS) to evaluate the quality of the included studies [16].

**Statistic analysis**

We used Stata ve.15.0® licensed for StataCorp, College Station, TX, USA for statistic analysis to
quantitatively synthesize the mortality rate and complication rate of VV ECMO for neonates with severe respiratory failure during hospitalization. The results were presented as a summary point estimate (in %) with 95% confidential interval (CI). The heterogeneity between the studies was analyzed by the chi-square test, and was quantitatively determined by $I^2$. The published guidelines quantify heterogeneity values as three levels: low ($I^2=25%-49\%$), moderate ($I^2=50%-74\%$), and high ($I^2\geq75\%$) [17]. A random-effects model using DerSimonian and Laird method for variance estimator was performed to report results [18]. Statistic significance was set at a $P$ less than 0.05 (two-tailed).

Results

Study selection

1263 studies (564 in Pubmed, 665 in Embase, 34 in Cochrane library) were initially reviewed and 4 studies were finally included with a total of 347 patients [17-20] (Fig. 1). We excluded the studies registered in the ELSO database to avoid overlapping with studies from the original center and to diminish selective bias. All the included studies were single center or multicenter observational studies, which were implemented in Europe or the United States and published in English. NOS was used to perform quality assessment since all the studies were non-RCTs. Two studies got 6 stars [19,22], and two studies got 8 stars [20,21], which demonstrated a high quality for each study.

Study Characteristics

Demographic data of patients, features of included studies, procedural details and equipment information of ECMO are presented in table1, table2, and table3, respectively. Three single center retrospective studies and one multicenter retrospective study were found. Two studies were performed 20 years ago, when polymethylpentene hollow fiber membrane technology was not available. All included studies reported complications and mortality of VV ECMO in the treatment of severe neonatal respiratory failure. Underlying diseases leading to respiratory failure were variable, mostly included MAS and PPHN. Three studies included only VV ECMO patients, while the remaining study included patients in combination with VV ECMO and VA ECMO. Outcomes were not reported independently in this study, but the proportion of patients received solely VV ECMO was more the 90%.
Mortality at hospital discharge ranged from 6% to 21%, and pooled mortality at hospital discharge was 12% (5%-18%) with a heterogeneity of $I^2=73.8\%$ (p=0.01) (Fig. 2). Two studies reported mortality during ECMO and after decannulation, with 10% (0.8%-19.2%) and 6.1% (2.6%-9.6%), respectively. Complications occurred during hospitalization including pneumothorax (20.6%), hypertension (20.4%), cannula dysfunction (20.2%), seizure (14.9%), renal failure requiring hemofiltration (14.7%), infectious complications (10.3%), thrombi (7.4%), intracranial hemorrhage or infarction (6.6%), hemolysis (5.3%), cannula site bleeding (4.4%), gastrointestinal bleeding (3.7%), oxygenator failure (2.8%), other bleeding events (2.8%), brain death (1.9%), and myocardial stun (0.9%) (table 4).

**Subgroup analysis**

Racial group, publication year, maximum cannula size, and age at the beginning of ECMO might be sources of heterogeneity between studies. So we performed subgroup analysis from these four aspects (Fig. 3, Fig. 4, Fig. 5, Fig. 6). The results showed that maximum cannula size and age at the beginning of ECMO were sources of heterogeneity between studies, while racial group and publication year were not sources of heterogeneity between studies. Besides, the heterogeneity between studies might also originate in disease severity, ECMO equipment type, medical center’s level, the experience of the medical staff who operates ECMO, and some other factors.

Because the included studies are fewer, we didn’t perform meta-regression analysis and publication bias.

**Discussion**

Our study showed that the survival rate of neonates with respiratory failure after receiving VV ECMO was 88%, higher than that (73%) of neonates with respiratory failure treated by ECMO according to ELSO registry report in January 2019 [11]. The reason might be that the data of ELSO come from the mixed population of VA ECMO and VV ECMO, and most patients who receive VA ECMO have hemodynamic instability and need cardiac support, thus reduce the survival rate. According to the ELSO database, the survival rate of VA ECMO for neonatal respiratory failure between 2012 and 2017 was 70%, while that of VV ECMO was 80% [12].
Our results also showed that mortality rate of neonates in the Kugdman et al.’s study was lowest [20], while that in the Chevalier et al.’s study was highest [22]. According to the ELSO database, neonates with MAS have the highest survival rate, followed by neonates with PPHN and CDH [6]. On one hand, neonates with MAS enrolled in the Kugdman et al.’s study might have more stable respiratory status, plus new treatment modalities (NO, HFV, PS) were used and the ECMO team was more experienced at that time, thus improve the survival rate. On the other hand, in the Chevalier et al.’s study, cannula applied on neonates was small, indicating that this group of neonates were small, and ECMO equipment was not advanced at the early time, all these factors might result in the relatively high mortality of this study.

An overall survival rate of 88% was seen in the 347 neonates, higher than that of other age groups by VV perfusion according to the ELSO database. Actually, different age groups have different disease spectrum. For neonatal ECMO, the most common diagnoses are CDH, MAS, and PPHN, accounting for almost 75% of all neonatal respiratory ECMO cases [12]. Whilst for pediatric ECMO and adult ECMO, the most common diagnoses are pneumonia and acute respiratory distress syndrome (ARDS) [6]. Prognosis of neonates with MAS, RDS and PPHN is promising due to good response to supplemental therapies such PS and iNO. In contrast, no studies have shown the beneficial effects of surfactant for adult and pediatric ARDS, which may explain the lower survival rate of pediatric and adult ECMO for respiratory failure caused by ARDS and pneumonia. In 2017, the international ARDS collaborative group provided the first consensus definition for neonatal ARDS [23]. However, the above studies of neonatal ECMO were performed in the pre-ARDS era, in which ARDS was usually considered as neonatal RDS. Actually, ARDS and RDS are two significant different diseases with different reactions to surfactant, and they should be diagnosed and treated independently. Besides, mortality rate is also associated with other factors such as annual hospital ECMO volume for neonates and adults, but not for pediatric cases [24].

In our study, complications including mechanical complications, bleeding, hypertension, seizure, and renal failure occurred during hospitalization. According to the ELSO, the most common complication of neonatal ECMO for respiratory failure is mechanical complication, such as clots in the ECMO circuit
[6], which is consistent with our study results. Bleeding and clots complications are multifactorial. Even though an ideal test of anticoagulation for patients is lacking, continuous unfractionated heparin and close monitoring of anticoagulation are required to reduce the risk of thrombosis and hemorrhage [25]. In our study, the rates of neurologic complications such as intracranial hemorrhage (ICH)/infarction and seizure are high as well, with 6.6% and 14.9%, respectively. When analyzing the ELSO registry report in 2016, neonates using ECMO have the highest rate of neurologic complications, with an ICH incidence of around 7.6% [6]. Various pre-existing factors like low birth weight, acidosis, hypoxia, hypotension, and organ failure have been found to be associated with neurologic injury. Besides, some ECMO factors such as modality of ECMO, hemorrhage, seizures, and development of new organ failure increase the risk of central neural system injuries further [26]. Therefore, understanding of risk factors associated with neonates and knowing how to deal with them are important to reduce complications. With the evolving indications for ECMO and the dramatically changed monitoring technology and supportive therapies over these years, the outcomes of patients have been improved greatly. Further attempts, such as by improving the equipment of ECMO, are needed to determine whether such events can be reduced.

Since a double-lumen catheter was designed in 1989, VV ECMO has been increasingly used in neonatal respiratory failure [27-28]. VV ECMO has a few advantages over VA ECMO. During VV ECMO, ligation of the carotid arteries is avoided, pulmonary circulation and coronary artery perfusion are maintained well, thus reduce the left ventricular afterload. Studies have showed that VV ECMO compared favorably to VA ECMO for cardiovascular support [29-30]. Some previous studies have also shown that VV ECMO was associated with lower rates of neurologic complications as compared with VA ECMO [27,31-32].

In this study, to minimize potential bias of observational study, we established inclusion and exclusion criteria strictly to provide accurate prevalence and incidence estimation, and we limited the minimum sample size of each study to 50 to reduce publication bias. Moreover, we excluded the studies published in the ELSO database to avoid data duplication and reduce selection bias, because only the selected medical centers have the chance to register in the ELSO database, which will increase
selection bias. Therefore, detailed VV ECMO data of other medical centers outside the ELSO database was collected in this study.

Limitations
There are some limitations in our study. Firstly, all the studies were non-RCT studies, which increased the risk of bias. Statistic quality of systematic review and meta-analysis is best assessed by RCTs. However, a pure randomized study is rare, whereas accurate studies are relatively common and provide most of the available evidence [33]. Secondly, only studies written in English were included, which might cause language bias. Thirdly, less than 10 studies were included, and publication bias and meta regression analysis were not performed, which might pose a potential risk of publication bias. Fourthly, the number of included studies was small and there was moderate heterogeneity among the studies. Fifthly, Some data in the original study could not be obtained, such as pump type and membrane type, and the baseline standards of each study might be inconsistent, many potential factors might play a role in our analysis. Lastly, the inclusion criteria might also result in the omission of potentially important studies, such as case reports and small sample studies. However, small sample studies might be affected by publication bias, historical bias, selective reporting, and other methodological deficiencies, which increase the risk of bias.

Conclusions
The results of this study showed that although VV ECMO treatment for neonatal respiratory failure might lead to some complications including pneumothorax, hypertension, cannula dysfunction, seizure, renal failure and so on, the survival rate during hospitalization is still high. Larger samples and higher quality of randomized controlled studies are needed to provide a more reliable basis for the application of VV ECMO in neonates with respiratory failure.

Abbreviations
ARDS: acute respiratory distress syndrome; CDH: congenital diaphragmatic hernia; CI: confidential interval; ELSO: extracorporeal life support organization; HFOV: high-frequency oscillatory ventilation; iNO: inhales nitric oxide; ICH: intracranial hemorrhage; MOOSE: meta-analysis of observational studies in epidemiology; MAS: meconium aspiration syndrome; NOS: Newcastle-Ottawa Scale; PPHN:
persistent pulmonary hypertension of newborn; RDS: respiratory distress syndrome; PS: pulmonary surfactant; PRISMA: preferred reporting items for systematic review and meta-analysis; RCTs: randomized controlled trials; VV ECMO: venovenous extracorporeal membrane oxygenation; VA ECMO: venoarterial extracorporeal membrane oxygenation

Declarations

Acknowledgements

We thank professor Luquan Li (Children's hospital of Chongqing Medical University, China) for copyediting and revising this manuscript.

Funding

No external funding was provided for this study.

Availability of data and materials

The data supporting our findings can be found by contacting us (400702@hospital.cqmu.edu.cn)

Author contributions

LB conceptualized and designed the study, revised the initial manuscript and approved the final manuscript as submitted. JX and LZ conducted literature search and data analysis; JX wrote the initial manuscript and approved the final manuscript as submitted. All the authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.
Competing interests

The authors declare that they have no competing interests.

References

1. Eriksen V, Nielsen LH, Klokker M, Greisen G. Follow-up of 5- to 11-year-old children treated for persistent pulmonary hypertension of the newborn. Acta Paediatr. 2009;98(2):304-309.

2. Walsh-Sukys MC, Bauer RE, Cornell DJ, Friedman HG, Stork EK, Hack M. Severe respiratory failure in neonates: mortality and morbidity rates and neurodevelopmental outcomes. J Pediatr. 1994;125(1):104-110.

3. Steinhorn RH. Treatment of hypoxemic respiratory failure in neonates: past, present and future. J Perinatol. 2016 Jun;36 Suppl 2:S1-2.

4. Kevin I Wheeler, Naomi McCallion, Colin J Morley, Peter G Davis, Claus Klingenberg. Volume-targeted versus pressure-limited ventilation in neonates. Cochrane Database Syst Rev. 2017 Oct; 2017(10): CD003666.

5. Frenckner B. Extracorporeal membrane oxygenation: a breakthrough for respiratory failure. J Intern Med. 2015; 278(6): 586-598.

6. Thiagarajan RR, Barbaro RP, Rycus PT, Mcmullan DM, Conrad SA, Fortenberry JD, et al. Extracorporeal Life Support Organization Registry International Report 2016. ASAIO J. 2017 Jan/Feb;63(1):60-67.

7. Gattinoni L, Pesenti A, Mascheroni D, Marcolin R, Fumagalli R, Rossi F, et al. Low-frequency positive-pressure ventilation with extracorporeal CO2 removal in severe acute respiratory failure. JAMA 1986, 256:881-886.

8. Hintz S, Suttner D, Sheehan A, Rhine W, Van Meurs K. Decreased use of neonatal extracorporeal membrane oxygenation (ECMO): how new treatment modalities have affected ECMO utilization. Pediatrics. 2000;106:1339-1343.
9. Christou H, Van Marter LJ, Wessel DL, Allred EN, Kane JW, Thompson JE, et al. Inhaled nitric oxide reduces the need for extracorporeal membrane oxygenation in infants with persistent pulmonary hypertension of the newborn. Crit Care Med. 2000;28:3722-3727.

10. Barrington K, Finer N, Pennaforte T, Altit G. Nitric oxide for respiratory failure in infants born at or near term. Cochrane Database Syst Rev. 2017;1:CD000399.

11. Extracorporeal Life Support Organization. ECLS Registry Report. 2019. http://www.elso.org/Registry/Statistics/InternationalSummary.aspx. Accessed Jan 2019.

12. Mahmood B, Newton D, Pallotto EK. Current trends in neonatal ECMO. Semin Perinatol. 2018;42:80-88.

13. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283:2008-2012.

14. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analysis of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

15. Vaquer S, de Haro C, Peruga P, Oliva JC, Artigas A. Systematic review and meta-analysis of complications and mortality of veno-venous extracorporeal membrane oxygenation for refractory acute respiratory distress syndrome. Ann Intensive Care. 2017;7:51.

16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603-
17. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta analysis. Stat Med. 2002;21:1539-1558.

18. Kontopantelis E, Reeves D. Performance of statistical methods for meta-analysis when true study effects are non-normally distributed: a comparison between DerSimonian-Laird and restricted maximum likelihood. Stat Methods Med Res. 2012;21:657-659.

19. Speggiorin S, Robinson S G, Harvey C, Westrope C, Faulkner GM, Kirkland P, et al. Experience with the Avalon bicaval double-lumen veno-venous cannula for neonatal respiratory ECMO. Perfusion. 2015; 30:250-254.

20. Kugelman A, Gangitano E, Taschuk R, Garza R, Riskin A, McEvoy C, et al. Extracorporeal membrane oxygenation in infants with meconium aspiration syndrome: A decade of experience with venovenous ECMO. Journal of Pediatric Surgery. 2005; 40:1082-1089.

21. Knight GR, Dudell GG, Evans ML, Grimm PS. A comparison of venovenous and venoarterial extracorporeal membrane oxygenation in the treatment of neonatal respiratory failure. Crit Care Med. 1996; 24:1678-1683.

22. Chevalier J Y, Couprie C, Larroquet, M, Renolleau S, Durandy Y, Costil J, et al. Venovenous single lumen cannula extracorporeal lung support in neonates. A five year experience. ASAIO Journal. 1993; 39: M654-M658.

23. De Luca D, van Kaam AH, Tingay DG, Courtney SE, Danhaive O, Carnielli VP, et al. The Montreux definition of neonatal ARDS: biological and clinical background behind the description of a new entity. Lancet Respir Med 2017;5:657-666.

24. Barbaro RP, Odetola FO, Kidwell KM, Paden ML, Bartlett RH, Davis MM, et al. Association of Hospital-Level Volume of Extracorporeal Membrane Oxygenation Cases
and Mortality. Analysis of the Extracorporeal Life Support Organization Registry. Am J Respir Crit Care Med. 2015;191:894-901.

25. Barton R, Ignjatovic V, Monagle P. Anticoagulation during ECMO in neonatal and paediatric patients. Thromb Res. 2019;173:172-177.

26. Mehta A, Ibsen LM. Neurologic complications and neurodevelopmental outcome with extracorporeal life support. World J Crit Care Med. 2013;2:40-47.

27. Anderson HL III, Otsu T, Chapman RA, Barlett RH. Venovenous extracorporeal life support in neonates using a double lumen catheter. ASAIO Trans. 1989;35:650-653.

28. Otsu T, Merz SI, Hultquist KA, Attorri RJ, Anderson HL 3rd, Scheffler DE, et al. Laboratory evaluation of a double lumen catheter for venovenous neonatal ECMO. ASAIO Trans. 1989;35:647-650.

29. Cornish JD, Heiss KF, Clark RH, Strieper MJ, Boecler B, Kesser K. Efficacy of venovenous extracorporeal membrane oxygenation for neonates with respiratory and circulatory compromise. J Pediatr. 1993; 122: 105-109.

30. Roberts N, Westrope C, Pooboni SK, Mulla H, Peek GJ, Sosnowski AW, et al. Venovenous extracorporeal membrane oxygenation for respiratory failure in inotrope dependent neonates. ASAIO Journal. 2003; 49: 568-571.

31. Dimmitt RA, Moss RL, Rhine WD, Benitz WE, Henry MC, Vanmeurs KP. Venoarterial versus venovenous extracorporeal membrane oxygenation in congenital diaphragmatic hernia: the Extracorporeal Life Support Organization Registry, 1990-1999. J Pediatr Surg. 2001; 36: 1199-1204.

32. Guner YS, Khemani RG, Qureshi FG, Wee CP, Austin MT, Dorey F et al. Outcome analysis of neonates with congenital diaphragmatic hernia treated with venovenous vs venoarterial extracorporeal membrane oxygenation. J Pediatr Surg. 2009; 44: 1691-1701.
Chandler J, Cumpston M, Thomas J, Higgins JPT, Deeks JJ, Clarke MJ. Chapter I: Introduction. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated August 2019). Cochrane, 2019. http://www.training.cochrane.org/handbook. Accessed Aug 2019.

Tables
Please see the supplementary files section to view the tables.

Figures
Figure 1

Flowchart of study screening for the systematic review and meta-analysis
Figure 2

Forest plot of pooled mortality during hospitalization
| Study ID | ES (95% CI) | Weight |
|---------|-------------|--------|
| USA     |             |        |
| Kugelman et al (2005) | 0.06 (0.02, 0.11) | 29.75 |
| Knight et al (1996) | 0.09 (0.02, 0.17) | 23.14 |
| Subtotal (I-squared = 0.0%, p = 0.492) | 0.07 (0.03, 0.11) | 52.89 |
| Europe  |             |        |
| Speggiorin et al (2015) | 0.11 (0.04, 0.18) | 24.08 |
| Chevalier et al (1993) | 0.21 (0.14, 0.29) | 23.04 |
| Subtotal (I-squared = 72.7%, p = 0.056) | 0.16 (0.06, 0.26) | 47.11 |
| Overall (I-squared = 73.8%, p = 0.010) | 0.12 (0.05, 0.18) | 100.00 |

NOTE: Weights are from random effects analysis

Figure 3

Forest plot of mortality across racial groups
| Study ID | % | ES (95% CI) | Weight |
|----------|---|-------------|--------|
| >2010 (year) | 0.11 (0.04, 0.18) | 24.08 |
| Speggiorin et al (2015) | | |
| Subtotal (I-squared = .% p = .) | 0.11 (0.04, 0.18) | 24.08 |
| 2000-2010 (year) | 0.06 (0.02, 0.11) | 29.75 |
| Kugelman et al (2005) | | |
| Subtotal (I-squared = .% p = .) | 0.06 (0.02, 0.11) | 29.75 |
| <2000 (year) | 0.09 (0.02, 0.17) | 23.14 |
| Knight et al (1996) | | |
| Chevalier et al (1993) | 0.21 (0.14, 0.29) | 23.04 |
| Subtotal (I-squared = 79.1%, p = 0.029) | 0.15 (0.03, 0.27) | 46.18 |
| Overall (I-squared = 73.8%, p = 0.010) | 0.12 (0.05, 0.18) | 100.00 |

NOTE: Weights are from random effects analysis

Figure 4
Forest plot of mortality from different publication years
Figure 5

Forest plot of mortality with different maximum cannula sizes
Figure 6

Forest plot of mortality at different ages at the beginning of ECMO

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

PRISMA 2009 checklist.doc
Table 1.docx
Table 2.docx
Table 3.docx
Table 4.docx